Cambio - Excellence in Molecular Biology

Oligo Synthesis

Oligo Synthesis : CEPs

Prices quoted are for single packs only. For multiples of the same product please request a quote. Some of Glen's products are hazardous and may be subject to additional shipping charges. Full product information is available on Glen Research's website.

5',8-Cyclo-dA CE Phosphoramidite

5',8-Cyclo-dA CE Phosphoramidite

Glen Research

Description

5'8-Cyclo-dA CE Phosphoramidite

Structure

Catalog Number: 10-1098-xx

Description: 8,5'-Cyclo-dA CE Phosphoramidite

5'-Dimethoxytrityl-N-benzoyl-8,5'-cyclo-2'-deoxyAdenosine,
3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite
Formula: C47H50N7O7P M.W.: 855.92 F.W.: 311.19

Diluent: Anhydrous Acetonitrile/Dichloromethane 1:3 (v/v)
Coupling: 3 minute coupling time is recommended. Due to the steric hindrance at the 5' hydroxyl, the coupling time for the phosphoramidite immediately following the addition of the 8,5'-Cyclo-dA should be increased to 6 minutes.
Deprotection: No changes needed from standard method recommended by synthesizer manufacturer.
Storage: Freezer storage, -10 to -30°C, dry
Stability in Solution: 2-3 days

One of the major sources of DNA damage in all organisms is the UV component of sunlight. The predominant reaction induced by UV light on DNA is dimerization of adjacent pyrimidine bases leading to cyclobutane dimers (CPDs). The dimers formed in the most significant quantity are the cis-syn cyclobutane dimer of two thymine bases. Although formed routinely, these dimer products are efficiently excised and repaired enzymatically (nucleotide excision repair) or the dimerization is reversed by photolase enzymes. These lesions have been connected to the formation of squamous cell carcinomas. In addition, humans who lack ability to repair CPD lesions with high efficiency may be genetically predisposed to Xeroderma Pigmentosa (XP), a disease characterized by extreme sensitivity to sunlight and high frequency of skin cancer. Polymerases encountering unrepaired CPD lesions are quite error-prone, leading to incorrect base insertions and subsequent mutations.

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Protocols

MSDS

Glen Report 21.1: NEW PRODUCT - (5ÔS)-5Õ,8-CYCLO-DA CE PHOSPHORAMIDITE

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Applications & Benefits

DA CE PHOSPHORAMIDITE

DILUTION/COUPLING DATA

The table below shows pack size data and, for solutions, dilutions and approximate couplings based on normal priming procedures. Please link for more detailed usage information with the various synthesizers.

ABI 392/394
Cat.No. Pack
Size
Grams/
Pack
0.1M Dil.
(mL)
LV40 LV200 40nm 0.2µm 1µm 10µm
Approximate Number of Additions
10-1098-95 50µmoles .043grams .5 3.33 2 1.25 .91 .67 .17
10-1098-90 100µmoles .086grams 1 20 12 7.5 5.45 4 1
10-1098-02 0.25grams .25grams 2.92 84 50.4 31.5 22.91 16.8 4.2
Expedite
Cat.No. Pack
Size
Grams/
Pack
Dilution
(mL)
Molarity 50nm 0.2µm 1µm 15µm
Approximate Number of Additions
10-1098-95 50µmoles .043grams .75 .07 8.6 5.38 3.91 .54
10-1098-90 100µmoles .086grams 1.5 .07 23.6 14.75 10.73 1.48
10-1098-02 0.25grams .25grams 4.36 .07 80.8 50.5 36.73 5.05
Beckman
Cat.No. Pack
Size
Grams/
Pack
Dilution
(mL)
Molarity 30nm 200nm 1000nm

Approximate Number of Additions
10-1098-95 50µmoles .043grams .75 .07 10.2 6.38 4.64

10-1098-90 100µmoles .086grams 1.5 .07 25.2 15.75 11.45

10-1098-02 0.25grams .25grams 4.36 .07 82.4 51.5 37.45

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200

Related products

If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200